Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Resistance often emerges through mutations in the therapeutic target or activation of alternative signaling pathways. Mechanisms of acute tumor cell resistance to initial EGFR (EGFRi ... mediums were ...

Rather than considering the following points as weaknesses, I instead prefer to think of them as areas for future study: (1) Given the field's intense ... we present data from 5 cell lines ...

Uncovering methylation signatures and pathways associated with resistance to anti-EGFR therapy in colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual ...

The expression of TLS-associated genes in CD4+ T cells was significantly elevated, along with the upregulation of immune-related pathways, such as B cell activation signaling and IL-17-related ...

Previous studies have indicated that BRAF inhibitors alone do not achieve satisfactory outcomes, as they can lead to feedback activation of EGFR and reactivation of the MAPK pathway ... and HRAS (1%).

1 Center of Gerontology and Geriatrics and Laboratory of Metabolism ... Our findings demonstrate that DAPA can inhibit the MAPK signaling pathway, as confirmed by network pharmacology analysis and ...

The role of EGFR in KRASG12D-driven tumorigenesis was studied using mouse CRC organoids with KRAS-APC-TP53 mutations and ...

Heme oxygenase 1 (HO-1) has an influential yet insufficiently investigated effect on Sirtuin 1 (SIRT1), a histone deacetylase ...

In astrocytes grown in vitro, Ptprs expression increased after EGFR depletion and stimulation ... of psychedelic drugs that target the serotonin pathway on meningeal immune cells.

A total of 337 treatment-naïve patients with EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC were enrolled and randomized 1:1 to receive either limertinib or gefitinib.